sitagliptin/metformin grindeks 50 mg/1000 mg
as grindeks. - letonia - combinatii (sitagliptinum+metforminum) - compr. film. - 50mg/1000mg - analogi ai glp-1 combinatii de antidiabetice orale
sitagliptin/metformin grindeks 50 mg/850 mg
as grindeks. - letonia - combinatii (sitagliptinum+metforminum) - compr. film. - 50mg/850mg - analogi ai glp-1 combinatii de antidiabetice orale
sitagliptin/metformin sandoz 50 mg/1000 mg
rontis hellas medical and pharmaceutical products s.a. - grecia - combinatii (sitagliptinum+metforminum) - compr. film. - 50mg/1000mg - analogi ai glp-1 combinatii de antidiabetice orale
sitagliptin/metformin teva 50 mg/1000 mg
laboratorios liconsa s.a. - spania - combinatii (sitagliptinum+metforminum) - compr. film. - 50mg/1000mg - analogi ai glp-1 combinatii de antidiabetice orale
sitagliptin / metformin hydrochloride accord
accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetul zaharat, tip 2 - medicamente utilizate în diabet - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. , terapie triplă) ca adjuvant la dietă și exercițiu fizic, la pacienți controlați inadecvat cu doza maximă tolerată de metformin și o sulfoniluree. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
sitagliptin / metformin hydrochloride mylan
mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetul zaharat, tip 2 - medicamente utilizate în diabet - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , terapie triplă) ca adjuvant la dietă și exercițiu fizic, la pacienți controlați inadecvat cu doza maximă tolerată de metformin și o sulfoniluree. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
sitagliptin / metformin hydrochloride sun
sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetul zaharat, tip 2 - medicamente utilizate în diabet - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , terapie triplă) ca adjuvant la dietă și exercițiu fizic, la pacienți controlați inadecvat cu doza maximă tolerată de metformin și o sulfoniluree. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
sitagliptin/clorhidrat de metformin pharmazac 50 mg/1000 mg
remedica ltd. - cipru - combinatii (sitagliptinum+metforminum) - compr. film. - 50mg/1000mg - analogi ai glp-1 combinatii de antidiabetice orale
sitagliptin/clorhidrat de metformin pharmazac 50 mg/850 mg
remedica ltd. - cipru - combinatii (sitagliptinum+metforminum) - compr. film. - 50mg/850mg - analogi ai glp-1 combinatii de antidiabetice orale
janumet comprimate filmate 1000 mg + 50 mg
schering-plough central east ag - metforminum + sitagliptinum - comprimate filmate - 1000 mg + 50 mg